Bouvier NM. The Future of Influenza Vaccines: A Historical and Clinical Perspective. Vaccines (Basel). 2018 Aug 30;6(3).
For centuries, the development of vaccines to prevent infectious disease was an empirical process. From smallpox variolation in Song dynasty China, through the polysaccharide capsule vaccines developed in the 1970s, vaccines were made either from the pathogen itself, treated in some way to render it attenuated or non-infectious, or from a closely related non-pathogenic strain. In recent decades, new scientific knowledge and technologies have enabled rational vaccine design in a way that was unimaginable before. However, vaccines optimal against some infectious diseases, influenza among them, have remained elusive. This review will highlight the challenges that influenza viruses pose for rational vaccine design. In particular, it will consider the clinically beneficial endpoints, beyond complete sterilizing immunity, that have been achieved with vaccines against other infectious diseases, as well as the barriers to achieving similar success against influenza.
See Also:
Latest articles in those days:
- Phylogeography and gene pool analysis of highly pathogenic avian influenza H5N1 viruses reported in India from 2006 to 2021 3 hours ago
- Analysis of a diffusive epidemic model with a zero-infection zone 5 hours ago
- Quick detection of H5N1 avian influenza virus by surface enhanced Raman scattering(SERS) using aptamer capture 5 hours ago
- The critical role of RAGE in severe influenza infection: A target for control of inflammatory response in the disease 5 hours ago
- Human infection caused by avian influenza A (H10N5) virus 5 hours ago
[Go Top] [Close Window]